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Malignant pleural mesothelioma is an aggressive cancer, heterogeneous in its presentation
and behaviour. Despite an increasing knowledge about molecular markers and their
diagnostic and prognostic value, they are not used as much as they might be for
treatment allocation. It has been recently reported that mesothelioma cells that lack BAP1
(BRCA1 Associated Protein) are sensitive to inhibition of the EZH2 (Enhancer of Zeste
Homolog 2) histone methyltransferase. Since we observed strong H3K27me3 (histone H3
lysine 27 trimetylation) immunoreactivity in BAP1 wild-type mesothelioma biopsies, we
decided to characterize in vitro the response/resistance of BAP1 wild-type mesothelioma
cells to the EZH2 selective inhibitor, EPZ-6438. Here we demonstrate that BAP1 wild-type
mesothelioma cells were rendered sensitive to EPZ-6438 upon SIRT1 (Sirtuin 1) silencing/
inhibition or when cultured as multicellular spheroids, in which SIRT1 expression was lower
compared to cells grown in monolayers. Notably, treatment of spheroids with EPZ-6438
abolished H3K27me3 and induced the expression of CDKN2A (Cyclin-Dependent Kinase
Inhibitor 2A), causing cell growth arrest. EPZ-6438 treatment also resulted in a rapid and
sustained induction of the genes encoding HIF2a (Hypoxia Inducible Factor 2a), TG2
(Transglutaminase 2) and IL-6 (Interleukin 6). Loss of CDKN2 is a common event in
mesothelioma. CDKN2A silencing in combination with EPZ-6438 treatment induced
apoptotic death in mesothelioma spheroids. In a CDKN2A wild-type setting apoptosis
was induced by combining EPZ-6438 with 1-155, a TG2 selective and irreversible inhibitor.
In conclusion, our data suggests that the expression of CDKN2A predicts cell fate in
response to EZH2 inhibition and could potentially stratify tumors likely to undergo apoptosis.
Keywords: malignant pleural mesothelioma, EZH2 inhibitor, CDKN2A/p16ink4a, TG2, multicellular spheroidsINTRODUCTION
Malignant pleural mesothelioma (MPM) is a lethal cancer that originates from the mesothelial cells
aligning the pleura (1). The causal association of MPMwith asbestos exposure is well established and
supported by epidemiological and toxicological studies (2, 3). Although asbestos has been banned in
numerous countries, it continues to be used worldwide, and a rise in the MPM global incidence is
predicted (4).July 2021 | Volume 11 | Article 6784471
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MPM include pemetrexed with cisplatin or carboplatin (5). The
high number of non-responders to chemotherapy, as well as the
frequent recurrences of the disease (6, 7), suggests the presence of
drug-resistant clones within the tumor. Given that MPM
develops over many years and its growth rate is in most cases
quite low, it is highly likely that it has profound heterogeneity,
which makes it challenging to eradicate (8).
MPM intra- and inter-tumor heterogeneity manifests with
a morphological spectrum, ranging from epithelioid to
sarcomatoid tumors, with the biphasic subtype containing a
combination of both components (9). Besides histological
diversity, an increasing number of publications highlight the
importance of genetic and epigenetic intra-tumor heterogeneity
for MPM therapeutic resistance (10–13). Genomic interrogation
has revealed extensive interpatient heterogeneity with frequent
tumor suppressor inactivation being a dominant feature of
the mutation landscape mediated by multiple mechanisms,
which include single nucleotide variation, copy number losses,
gene fusions and splicing alterations (14, 15). Loss or mutation
of BAP1 (BRCA1 Associated Protein 1) coding gene is
recurrently identified in MPM and translates into nuclear
negativity for BAP1 expression (16). Levine’s group has
reported that BAP1 inactivation leads to upregulation and
dependence on the chromatin modifying Polycomb Repressive
Complex 2 (PRC2), comprising the methyltransferase EZH2
(Enhancer of Zeste Homolog 2), which trimethylates lysine 27
on histone H3 (H3K27me3) (17). Besides transcriptional
regulation, post-translational modifications of EZH2, including
phosphorylation (18), acetylation (19), ubiquitination (20),
sumoylation (21) and GlcNAcylation (22), have also been
found to be important for its expression and silencing function
on target genes.
Another common genetic alteration in MPM is the
homozygous deletion of the 9p21 locus, within a cluster of
genes that includes CDKN2A (cyclin-dependent kinase
inhibitor 2A) encoding p16ink4a (10, 23, 24). Heterozygous
deletion of CDKN2A is also commonly observed, sometimes at
higher levels than homozygous deletion, however, few reports
have addressed its role in MPM (25–27). Furthermore, a
discrepancy between p16ink4a protein expression and gene
deletion suggests that epigenetic mechanisms play a role in its
regulation (28). Indeed, H3K27me3-dependent repression of
CDKN2A transcription is a common feature of many tumors
(29, 30).
H3K27 methylation can also be influenced by hypoxia (31).
We have described that HIF-2a (Hypoxia Inducible Factor 2a)
induces the expression of the H3K27 demethylase KDM6B and
reduces the H3K27me3 repressive mark in MPM cells exposed to
chronic hypoxia (32). Furthermore, we have described that HIF-
2a-mediates the induction of TGM2 and the increase of TG2
(Transglutaminase 2) activity (33). TG2 is a multifunctional
enzyme that exhibits crosslinking, GTPase, cell adhesion,
protein disulfide isomerase, kinase, and scaffold activities (34).
TG2 expression and downstream IL-6 (Interleukin-6)
production have been profoundly correlated with primaryFrontiers in Oncology | www.frontiersin.org 2tumor growth, peritoneal spreading, distant metastasis and
resistance to standard cytotoxic agents (35, 36). We have
demonstrated that TG2 inhibition or TGM2 silencing causes,
under hypoxic conditions, a significant reduction of MPM cell
viability (33).
Here we describe strong H3K27me3 immunoreactivity in
tumor tissue samples obtained from patients diagnosed with
BAP1 wild-type MPM. Moreover, we report that the treatment of
MPM multicellular spheroids with an EZH2 selective inhibitor
induces CDKN2A expression and cell cycle arrest. Finally, we
describe the involvement of p16ink4a and TG2 in the control of
MPM apoptotic cell death in response to EZH2 inhibition.MATERIALS AND METHODS
Reagents and Antibodies
The polyclonal antibodies specific for histone H3 trimethyl lysine
27 (H3K27me3), histone H3, SIRT1, KDM6B and the
monoclonal antibodies specific for Poly (ADP-ribose)
polymerase 1 (PARP1), acetyl-lysine, HIF2a, BAP1 and
a-tubulin were purchased from Santa Cruz Biotechnology
(Santa Cruz CA, USA). Polyclonal antibody anti-p16ink4a was
from Cell Signaling Technology (Leiden, The Netherlands).
Polyclonal antibody specific for EZH2 was from Active Motif
(La Hulpe, Belgium). Anti-mouse and anti-rabbit IgG peroxidase
or FITC conjugated antibodies and chemical reagents were from
Sigma-Aldrich (St. Louis, MO, USA). ECL, nitrocellulose
membranes and protein assay kit were from Bio-Rad
(Hercules, CA, USA). Culture media, sera, antibiotics,
LipofectAMINE transfection reagent and the monoclonal
antibody specific for TG2 (TG100) were from Thermo Fisher
(Waltham, MA, USA). EX-527 and the EZH2-selective inhibitor,
EPZ-6438, were from Selleckchem (Houston, TX, USA). The
highly selective TG2 inhibitor, 1-155 (cell-permeable) was
designed and synthesized as previously documented (37, 38).
Immunohistochemistry on Formalin-Fixed
Paraffin-Embedded Tissue Specimens
BAP1 and histone H3 trimethyl lysine 27 (H3K27me3)
expression were evaluated by immunohistochemistry (IHC) in
eight biphasic MPM human biopsies using a BenchMark
standard automated immunostainer (Ventana Medical System,
Tucson, AZ, USA). Specific primary antibodies against the anti-
human BAP1 and the polyclonal antibodies specific for
H3K27me3 were used. BAP1 and H3K27me3 were considered
positive when a weak-to-strong nuclear positivity was shown.
Negative controls were obtained by replacing the primary
antibody by PBS. Non-neoplastic cells, such as vascular
endothelium or inflammatory cells, were considered as internal
positive controls. Slides were counterstained with hematoxylin.
Cell Cultures and Transfection
The biphasic MPM derived MSTO-211H cell lines was obtained
from the Istituto Scientifico Tumori (IST) Cell-bank, Genoa,
Italy; the epithelioid MPM BR95 cell line was kindly provided byJuly 2021 | Volume 11 | Article 678447
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Italy). Cells were grown in standard conditions in RPMI medium
supplemented with 10% FBS, 100 mg/ml streptomycin and 10 mg/ml
penicillin at 37°C in a humidified environment containing 5% CO2.
Mycoplasma infection was excluded by the use of Mycoplasma
PlusTM PCR Primer Set kit from Stratagene (La Jolla, CA, USA).
Cells grown to 80% confluence in tissue culture dishes were
transiently transfected with negative control or specific siRNAs
from Qiagen (Hilden, Germany) using LipofectAMINE reagent as
described by the manufacturer. To obtain cell number and viability
information following treatments, cell were trypsinized and stained
with Trypan blue; the number of cells considered viable (unstained
cells) was counted in a Bürker chamber within 5 min after staining.
Multicellular Spheroids
Multicellular spheroids were generated in non-adsorbent round-
bottomed 96-well plates, as previously described (31). The 96-
well plates were coated with a 1:24 dilution of polyHEMA (120
mg/ml) in 95% ethanol and dried at 37°C for 24 h. Before use,
plates were sterilized by UV light for 30 min. For generation of
multicellular spheroids, 1 × 104 cells were added into each well of
polyHEMA-coated 96-well plate and placed in a 37°C humidified
incubator with 5% CO2. Every 24 h, 50% of supernatant was
replaced with fresh medium ± 10 mM EPZ-6438 and/or 5 mM
1-155 inhibitors. For cell dissemination, spheroids treated for
48 h with or without EPZ-6438, were transferred to flat-
bottomed culture dishes and incubated in complete medium
for additional 24 h. Migration area was observed under
the microscope.
Immunofluorescence Staining
Cell spheroids were let to adhere for 1/2 h to poly-L-lysine coated
glass slides and then fixed in 4% paraformaldehyde,
permeabilized with 0.5% Triton X-100 in PBS and blocked in
3% BSA/PBS 10% FBS. The primary antibody (mouse anti-
H3K27me3 1:100) was incubated for 2 h at 4°C. The
fluorescent secondary antibody (rabbit anti-mouse IgG
antibody conjugated with fluorescein isothiocyanate (FITC);
1:100) was incubated for 1 h at 4°C. Fluorescent images were
captured using a Leica MB5000B microscope equipped with a
DFC480 R2 digital camera and a Leica Application Suite
(LAS) software.
Cell Cycle Analysis
For cell cycle/apoptosis analysis, 5 × 105 cells were silenced for
SIRT1 and treated or not with EPZ-6438 for 48 h at 37°C in a 5%
CO2 atmosphere. After incubation, detached and suspended cells
were harvested in complete RPMI and centrifuged at 500×g for
10 min. Pellets were washed with PBS, pH 7.4, in ice-cold 75%
ethanol at 4°C, treated with 100 mg/ml RNAse A for 1 h at 37°C,
stained with 25 mg/ml propidium iodide and finally analyzed by
using a Bio-Rad S3e Cell Sorter (Hercules, CA, USA) and the
Modfit software (Verity Software House, Topsham, ME, USA).
Cell Lysis and Immunoblot
Cells were extracted with 1% NP-40 lysis buffer (50 mM Tris–
HCl pH 8.5 containing 1% NP-40, 150 mMNaCl, 10 mM EDTA,Frontiers in Oncology | www.frontiersin.org 310 mMNaF, 10 mMNa4P2O7 and 0.4 mMNa3VO4) with freshly
added protease inhibitors (10 mg/ml leupeptin, 4 mg/ml pepstatin
and 0.1 Unit/ml aprotinin). Lysates were centrifuged at 13.000×g
for 10 min at 4°C and the supernatants were collected and
assayed for protein concentration with the Bradford assay
method (Bio-Rad). Histones were acid extracted from nuclei
with 0.4 N HCl and precipitated with trichloroacetic acid (TCA),
followed by washing with ice-cold acetone containing 0.006%
HCl, and then with pure ice-cold acetone. The resulting pellets
were air-dried, dissolved in a minimal volume of sterile distilled
water and the protein concentration was determined.
Proteins were separated by SDS-PAGE under reducing
conditions. Following SDS-PAGE, proteins were transferred to
nitrocellulose, reacted with specific antibodies and then detected
with peroxidase-conjugate secondary antibodies and
chemioluminescent ECL reagent. Digital images were taken
with the Bio-Rad ChemiDoc™ Touch Imaging System and
quantified using Bio-Rad Image Lab 5.2.1.
RNA Isolation and Real-Time PCR
Total RNA was extracted using the guanidinium thiocyanate
method. Starting from equal amounts of RNA, cDNA used as
template for amplification in the real-time PCR (5 µg), was
synthesized by the reverse transcription reaction using RevertAid
Minus First Strand cDNA Synthesis Kit from Fermentas-
Thermo Scientific (Burlington, ON, Canada), using random
hexamers as primers, according to the manufacturer’s
instructions. Some 20 ng of cDNA were used to perform RT-
PCR amplification of mRNA. The real-time reverse
transcription-PCR was performed using the double-stranded
DNA-binding dye SYBR Green PCR Master Mix (Fermentas-
Thermo Scientific) on an ABI GeneAmp 7000 Sequence
Detection System machine, as described by the manufacturer.
The instrument, for each gene tested, obtained graphical Cycle
threshold (Ct) values automatically. Triplicate reactions were
performed for each marker and the melting curves were
constructed using Dissociation Curves Software (Applied
Biosystems, Foster City, CA, USA), to ensure that only a single
product was amplified.
Statistical Analysis
Statistical evaluation of the differential analysis was performed by
one-way ANOVA and Student’s t-test.RESULTS
BAP1 Wild-Type Mesotheliomas Exhibit
H3K27me3 Immunoreactivity
BAP1 is inactive in 40–60% of MPM patients (10, 14). Recent
evidence suggesting the potential efficacy of EZH2 inhibition in
preclinical models of BAP1 loss led to a phase II clinical trial
evaluating the EZH2 inhibitor Tazemetostat (EPZ-6438) in
MPM patients with inactive BAP1 (NCT02860286).
Here, we examined the H3K27me3 status in biopsies obtained
at diagnosis from a cohort of BAP1 positive, biphasic MPM,July 2021 | Volume 11 | Article 678447
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showed strong BAP1 and H3K27me3 nuclear staining in the
majority of tumor cells (3+ in >67%) (Figures 1A–D and Figures
S1A–F). A minority of cells displayed a reduced H3K27me3
nuclear staining, however, further and deeper investigation is
needed in order to associate significant differences in intensity
with the epithelioid or the sarcomatoid component of the tumor.
Strong immunoreactivity for H3K27me3 was also observed in the
non-neoplastic infiltrating inflammatory cells (Figures S1E, F).
Inhibition of EZH2 Activity Exerts Anti-
Proliferative Effect in BAP1 Wild-Type
MPM Spheroids
Based on IHC results, we decided to use the MSTO-211H cell line,
established from the pleural effusion of a patient with biphasic
mesothelioma, as a model to better characterize in vitro the
response of BAP1 wild-type MPM to EPZ-6438, a potent and
selective inhibitor of the H3K27 methyltransferase EZH2.
We first report, as described by LaFave et al. (17), that inhibition
of the EZH2 methyltransferase activity, by EPZ-6438, did not affect
MSTO-211H cell viability, when cultured as two-dimensional (2D)
monolayer (Figures 2A, a, b, B). Differently, we observed that
EPZ-6438 treatment significantly reduced the size andmodified the
architecture of MSTO-211H multicellular spheroids (MCS), as
evidenced by bright field and pseudo-color images (Figures 2A,
c–f), and reduced cell dissemination after re-adhesion of MCS toFrontiers in Oncology | www.frontiersin.org 4flat-bottomed plates (Figures 2A, g, h). Cell counts confirmed that
the reduction in size of EPZ-6438 treated MCS was due to a lower
number of cells and not to an increase in cell packing density
(Figure 2B). Immunofluorescence images in Figures 2A(i, j) show
that H3K27me3 was spatially restricted to the external proliferating
region of the spheroids and was completely abolished by EPZ-6438
treatment. In agreement, we documented high expression of the
H3K27 demethylase KDM6B in the internal hypoxic zone of the
spheroids, enriched in HIF2a expression (Figure S2) (31).
Western-blot analysis confirmed an increase in H3K27
methylation in MSTO-211H MCS versus 2D culture that was
completely abolished by EPZ-6438 treatment (Figure 2C).
SIRT1 Inhibition Confers Sensitivity to
EZH2 Inhibition in BAP1 Wild-Type
MPM Cells
It has been reported that depletion of the NAD-dependent
deacetylase SIRT1 increases EZH2 protein acetylation, stability
and its repressive effect on target genes (19). In our previous
studies, we demonstrated lactate-mediated SIRT1 downregulation,
in MPM cells cultured as MCS compared to monolayer (39). Here,
alongwithSIRT1downregulation,weobserved increasedexpression
of EZH2 in MSTO-211H MCS (Figure 3A). To evaluate the
regulatory role of SIRT1 on EZH2 expression and activity in BAP1
wild-typeMPM,we treatedMSTO-211H cells in 2Dwith the SIRT1




FIGURE 1 | BAP1 wild-type MPM tumor biopsies exhibit high immunoreactivity for H3K27me3. Representative images of immunostaining. Byphasic MPM tissue samples
were stained for BAP1 (A, B) and H3K27me3 (C, D). Images were captured at magnification ×40 (A, C) and ×200 (B, D) using light microscopy. Scale bar = 100 mM.July 2021 | Volume 11 | Article 678447
Pinton et al. CDKN2A Role in EZH2 InhibitionIn MSTO-211H cells treated with EX-527, we demonstrated the
expression of EZH2 protein significantly increased, whereas EZH2
mRNA levels remained stable (Figure 3B). In this experimental
condition, we demonstrated, by immunoprecipitation experiments,
an increase in EZH2 acetylation (Figure 3C). In accordance with
increased EZH2 protein expression and acetylation, we observed
increased H3K27me3 level in EX-257 treated cells (Figure 3B). The
combined treatment of EPZ-6438 and EX-527 resulted in a
significant reduction in the MSTO-211H growth rate (Figure 3D).
H3K27 demethylation was confirmed by Western blot
analysis (Figure 3E).
To confirm the role of SIRT1 in cell response to EPZ-6438
treatment, we transfected MSTO-211H cells with specific siRNAs
and evaluated the effect on cell proliferation. SIRT1 silencing was
confirmed by RT-PCR and Western blot analyses (Figure 3F).
Comparable EPZ-6438 anti-proliferative effect, accompanied by a
G1 phase cell cycle arrest, was observed in SIRT1 silenced cellsFrontiers in Oncology | www.frontiersin.org 5(Figures 3G, H). We observed that EPZ-6438 treatment induced
the expression of CDKN2A, encoding for the cell cycle inhibitor
p16ink4a, in SIRT1 silenced cells cultured as monolayer (Figure 3I),
but not in cells transfected with negative control siRNA.
EZH2 Inhibition Mediates Strong Induction
of CDKN2A in MPM Spheroids
Notably, in EPZ-6438 treated MSTO-211H MCS, we observed a
strong induction of CDKN2A within 24 h, with a gradual
increase at 48 and 72 h (Figures 4A, B). Comparable results
were observed in the BAP1/CDKN2A wild-type BR95 MPM cells,
cultured as MCS (Figure S3).
Moreover, here we show that treatment with EPZ-6438
strongly induced the expression of genes encoding HIF2a and
KDM6B, starting from 24 h of treatment (Figures 4A, B). In
untreated MCS the expression of these genes increased starting
from 72 h of culture, as we had previously described (31).A
B C
FIGURE 2 | EZH2 inhibition displays an antiproliferative effect in BAP1 wild-type MPM MCS. (A) Representative phase contrast images (×40 magnification) of MSTO-211H
cultured as monolayer (a, b) or MCS (1 of 12) (c, d) with relative pseudo-color images (e, f). Representative phase contrast images of dissemination of MSTO-211H MCS
(one of 12) after 24 h re-adhesion to flat-bottomed plates, post 48 h treatment in the presence or absence of EPZ-6438 (g, h). H3K27me3 immunofluorescence image of
MSTO-211H MCS treated for 48 h, with or without EPZ-6438 (i, j). Scale bar = 100 mM. (B) Bar graph shows the percentage of viability of MSTO-211H cells cultured as
monolayer or MCS ± 48 h treatment with EPZ-6438. Each bar represents mean of three independent experiments ± s.d., *p ≤0.05. (C) Representative Western blot
analysis of H3K27me3 in MSTO-211H cultured in 2D or as MCS ± 48 h treatment with EPZ-6438. histone H3 was used as loading control.July 2021 | Volume 11 | Article 678447
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cell cycle arrest or a permanent exit from cycling, MSTO-211H
MCS were treated 48 h with EPZ-6438, followed by its wash-off,
and continued growth in normal culture medium for an
additional 48 h. Interestingly, the cell growth and architecture
of MSTO-211H MCS (Figures 4C, a–f, D) along with CDKN2A
expression (Figure 4E) returned back to control levels after 48 h
of EPZ-6438 removal.
EZH2 Inhibition Induces Apoptosis in
CDKN2A Silenced MPM Cells
As homozygous and heterozygous deletions of the 9p21 locus,
encompassing CDKN2A, are frequent in MPM, we hypothesized
that p16ink4a induction was responsible for the arrest in cell growth
observed in MCS treated with EPZ-6438 and that cells deleted for
this gene could be insensitive to EZH2 inhibition. We nextFrontiers in Oncology | www.frontiersin.org 6generated MCS from CDKN2A silenced MSTO-211H cells to
counteract its induced expression in response to EPZ-6438
treatment. Different to our hypothesis, EPZ-6438 treatment
induced apoptosis in CDKN2A silenced MSTO-211H MCS, as
demonstrated by bright field (Figures 4F, a–c) and pseudo-color
microscope images (Figures 4F, d–f), PARP1 cleavage (Figure 4H),
BCL2L11 (encoding BIM) and BBC3 (encoding PUMA) induction
(Figure 4F). CDKN2A silencing was confirmed by Western blot
(Figure 4G) and RT-PCR (Figure 4H) analysis.
Dual Inhibition of EZH2 and TG2 Exhibits
Proapoptotic Synergy in CDKN2A
Wild-Type MPM Cells
Looking for a potential druggable target in CDKN2A expressing
MPM MCS, we tested whether EZH2 inhibition, by inducing
rapid HIF2 expression, could also lead to increased TG2A B C D
F G H I
E
FIGURE 3 | SIRT1 inhibition increases EZH2 expression, acetylation and activity. (A) Representative Western blot analysis of EZH2 and SIRT1 in MSTO-211H cells
cultured 48 h as monolayer or as MCS. Tubulin was used as loading control. (B) Representative Western blot analysis and RT-PCR analysis of EZH2 expression and of
H3K27 trimethylation (H3K27me3) in MSTO-211H cells cultured as monolayer ± 48 h EX527 treatment. Tubulin and histone H3 were used as loading control and 18S
rRNA as housekeeping gene. (C) Immunoprecipitation of EZH2 from lysates of MSTO-211H cells ± EX527 48 h treatment. Lysine acetylation and EZH2 were detected by
Western blot analysis with the respective antibodies (AcLys and EZH2). (D) Bar graph shows the percentage of viability of MSTO-211H cells cultured as monolayer ±
48 h treatment with EPZ-6438 or EPZ-6438/EX527 combination. Each bar represents mean of three independent experiments ± s.d., *p ≤0.05. (E) Representative
Western blot analysis of H3K27me3 in MSTO-211H cells treated 48 h with EPZ-6438 or EPZ-6438/EX527 combination. Histone H3 was used as loading control.
(F) Representative Western blot analysis and RT-PCR analysis of SIRT1 expression in MSTO-211H cells transfected with negative control (NC) or SIRT1 specific siRNAs
(SIRT1 siRNA). Tubulin was used as loading control and 18S rRNA as housekeeping gene. (G) Bar graph shows the percentage of viability of MSTO-211H cells
transfected with negative control (NC) or SIRT1 specific siRNAs (SIRT1 siRNA) after 48 h treatment ± EPZ-6438. Each bar represents mean of three independent
experiments ± s.d., *p ≤0.05. (H) Bar graph representing the percentage of cells in G0/G1, S and G2 phase of MSTO-211H cells transfected with negative control (NC)
or SIRT1 specific siRNAs (SIRT1 siRNA) and treated or not, 48 h, with EPZ-6438. Bars represent the means of three measurements ± s.d., *p <0.05. (I) Representative
quantitative RT-PCR analysis of CDKN2A, EZH2 and SIRT1 in MSTO-211H cells transfected with negative control (NC) or SIRT1 specific siRNAs (SIRT1 siRNA) and
treated 48 h ± EPZ-6438. 18S rRNA was used as housekeeping gene.July 2021 | Volume 11 | Article 678447





FIGURE 4 | EZH2 inhibition induces cell cycle arrest in CDKN2A+ or apoptosis in CDKN2A- MPM MCS (A) Representative RT-PCR analysis of CDKN2A, EPAS1,
KDM6B and EZH2 in MSTO-211H MCS treated or not 24, 48 and 72 h with EPZ-6438. (B) CDKN2A, EPAS1, KDM6B and EZH2 mRNA expression (fold increase
over Ctrl) after 48 h treatment with EPZ-6438 of MSTO-211H MCS confirmed by Real time PCR (qPCR). 18S rRNA was used as housekeeping gene.
(C) Representative phase contrast images (×40 magnification) (a–c) and relative pseudo-color images (d–f) of MSTO-211H MCS treated ± EPZ-6438 for 96 h or
treated for 48 h with EPZ-6438 and, after wash-off, grown for additional 48 h in normal medium. (D) Bar graph shows the percentage of viability of MSTO-211H
MCS treated 96 h with EPZ-6438 or treated for 48 h with EPZ-6438 and, after wash-off, grown for additional 48 h in normal medium. Each bar represents mean of
three independent experiments ± s.d., *p ≤0.05. (E) Representative quantitative RT-PCR analysis of CDKN2A in MSTO-211H MCS treated as described above. 18S
rRNA was used as housekeeping gene. (F) Representative phase contrast images (×40 magnification) (one of 12) (a–c) and relative pseudo-color images (d–f) of
MSTO-211H MCS transfected with negative control (NC) siRNAs or CDKN2A specific siRNAs (CDKN2A siRNA) and treated ± EPZ-6438, 48 h. Scale bar = 100 mM.
(G) Representative Western blot analysis of p16ink4a, PARP1 and cleaved PARP1 in MSTO-211H MCS transfected with negative control (NC) siRNAs or CDKN2A
specific siRNAs (CDKN2A siRNA) and treated with or without EPZ-6438 for 48 h. Tubulin was used as loading control. (H) Representative RT-PCR analyses of
CDKN2A, BCL2L11 and BBC3 in MSTO-211H MCS transfected with negative control (NC) siRNAs or CDKN2A specific siRNAs (CDKN2A siRNA) and treated, 48 h,
with EPZ-6438. 18S rRNA was used as housekeeping gene.Frontiers in Oncology | www.frontiersin.org July 2021 | Volume 11 | Article 6784477
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expression and that TG2 activity is essential for MPM cell
survival under prolonged hypoxic condition. As shown in
Figures 5A, C, EPZ-6438 induced the expression of EPAS1,
TGM2 and its target IL-6 at 48 h treatment in MSTO-211H and
in BR95 MCS (Figures S3C, D).
In order to test the importance of TG2 induction in
preventing apoptosis, we treated MSTO-211H cells, cultured as
MCS, with EPZ-6438 and the cell permeable TG2 selective
inhibitor, 1-155, as single agents or in combination, for 48 h.
As documented by bright field (Figures 5B, a–d) and pseudo-
color microscope images (Figures 5B, e–h) the two drugs
synergized in reducing MCS size. By Western-blot analysis, we
observed a slow induction of TG2 expression in response to EPZ-
6438 treatment and, as expected, accelerated breakdown in
response to 1-155 treatment (Figure 5D). The EPZ-6438/1-155
combined treatment induced apoptosis as documented by
increased PARP1 cleavage (Figure 5D), BCL2L11 and BBC3
expression, as documented by RT-PCR (Figure 5A) and Real
Time PCR (Figure 5C), 1-155 treatment did not modify the
EPZ-6438 induced expression of CDKN2A, EPAS1 and TGM2,Frontiers in Oncology | www.frontiersin.org 8but significantly reduced the expression of the gene encoding
IL-6 (Figures 5A, C).DISCUSSION
MPM is known to show intrinsic therapy resistances and is so far
incurable. Therefore, establishment of new therapies for this
disease could be a valuable addition to current treatment options.
The high number of non-responders to chemotherapy (6), as
well as the frequent recurrences of the disease (7), suggests a high
degree of genetic heterogeneity within individual tumors. In
concert with genetic variation, dynamic regulation of the
epigenetic state may have important consequences for tumor
plasticity and biology. Recent work has implicated mutation and/
or dysregulated expression of histone lysine methyltransferases
(KMTs) and demethylases (KDMs) in cancer (40).
Among KMTs, EZH2 has been reported to be overexpressed in
various cancers, including MPM, and particularly to be associated
with aggressiveness and poor prognosis. Pharmacological
inhibition of EZH2 by 3-Deazanplanocin A (DZNep), anA B
C
D
FIGURE 5 | Dual inhibition of TG2 and EZH2 exhibits pro-apoptotic synergy in MPM MCS. (A) Representative RT-PCR of EPAS1, TGM2, IL6, BCL2L11, BBC3,
CDKN2A, and EZH2 expression in MSTO-211H MCS untreated or treated 48 h with EPZ-6438 and 1-155 as single agents or in combination. 18S rRNA was used
as housekeeping gene. (B) Representative phase contrast images (×40 magnification) (one of 12) (a–d) and relative pseudo-color images (e–h) of MSTO-211H MCS
untreated or treated 48 h with EPZ-6438 and 1-155 as single agents or in combination. Scale bar = 100 mM. (C) Real Time PCR (qPCR) analysis of EPAS1, TGM2,
IL6, BCL2L11, BBC3 and CDKN2A expression in MSTO-211H MCS untreated or treated 48 h with EPZ-6438 and 1-155 as single agents or in combination. 18S
rRNA was used as housekeeping gene. Each bar represents mean of three independent experiments ± s.d., *p ≤0.05. (D) Representative Western blot analysis of
TG2, PARP1 and cleaved PARP1 in MSTO-211H MCS untreated or treated 48 h with EPZ-6438 and 1-155 as single agents or in combination. Tubulin was used as
loading control.July 2021 | Volume 11 | Article 678447
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shown to effectively inhibit the growth of MPM cells (41, 42). A
phase II clinical trial (NCT02860286) of Tazemetostat (EPZ-6438),
a potent and selective EZH2 inhibitor, inMPMwith inactive BAP1
has shown promising results (43).
However, BAP1 inactivation and H3K27me3 positivity in
tissues may be sufficient, but not essential to predict response
toEZH2 inhibition.Hereweuncovered anantiproliferativeactivity
of EPZ-6438 in BAP1 wild-typeMPMcells, when cultured in vitro
as three-dimensional (3D) multicellular spheroids, but not when
grown in conventional two-dimensional (2D) monolayers.
Consistent evidence suggests that preclinical models based on
standard 2D culture of cancer cells largely fail to predict drug
efficacy, because they do not recapitulate the three-dimensional
architecture, heterogeneity and complexity of human tumors
(44). Multicellular tumor spheroids formed from established
tumor cell lines, approximating physiologic conditions, may
contribute to bridging this gap.
We show by immunofluorescence that EPZ-6438 treatment
nearly abolished H3K27 trimethylation, which was spatially
restricted to only the external oxygenated region of the spheroid.
In agreement with this, we have previously demonstrated that
expression of the H3K27 demethylase KDM6B was mostly
restricted to the internal hypoxic core of MPM MCS, enriched in
HIF2a expression (31).
It has been described that, under metabolic or hypoxic stress,
changes in NAD+/NADH are key events that initiate the cellular
adaptation processes. The NAD+ level and NAD+/NADH ratio
decrease during hypoxia and this is associated with SIRT1
downregulation and increased acetylation (45). We observed
that SIRT1 silencing or inhibition, with EX-527, resulted in
increased EZH2 protein acetylation and stability. In accordance
with increased EZH2 protein expression, we observed increased
H3K27me3 levels. It has been described that acetylated EZH2
exerts a gain-of-function in cells and promotes lung cancer
progression (19). Interestingly, the observed highest levels of
global H3K27me3 in MPM cells might indicate a higher degree
of addiction towards EZH2 activity and explain increased
sensitivity to its inhibition (Figures 6A, B).
In low SIRT1 conditions, EPZ-6438 treatment significantly
reduced MPM cell proliferation, arresting cells in G0/G1 phase.
We observed that EPZ-6438 treatment significantly reduced the
size and modified the architecture of MPMMCS in which SIRT1
was expressed at lower and EZH2 at higher levels, compared to
the cells cultured in 2D. Notably, in EPZ-6438 treated MCS, we
observed a strong induction of CDKN2A, encoding for the cell
cycle inhibitor p16ink4a. p16ink4a exerts tumor suppressive
function by inhibiting the activities of the cyclin D-dependent
kinases, CDK4 and CDK6, and preventing the retinoblastoma
protein (Rb) phosphorylation and dissociation from the
transcription factor E2F1. This biochemical pathway, essential
for the transition from G1 to S phase, is frequently disrupted in
tumor cells, by either deletions or inactivating mutations.
Furthermore, the literature supports that H3K27me3 regulates
CDKN2A expression and that EZH2 repression of CDKN2A is a
critical control point to promote transformation (46).Frontiers in Oncology | www.frontiersin.org 9It has been described that several stress stimuli may activate
p16ink4a expression to orchestrate cell cycle exit and senescence
response. Cellular senescence is a potent tumor suppressor
mechanism, acting in coordination with the immune system to
clear potentially malignant cells from the tissues. However,
senescence and cancer might be considered related endpoints
of accumulating cellular damage (24).
CDKN2A induction and cell cycle arrest were reverted upon
EPZ-6438 removal, indicating growth inhibition and not
cytotoxicity in cells exposed to the treatment. Indeed, our
results show that MPM cells in which CDKN2A/p16ink4a was
induced were more resistant to apoptosis than CDKN2A silenced
cells (Figure 6C).
Several studies have since demonstrated the reversibility of full-
featured senescence, indicating that pre-senescent or early
senescent cells are poised to re-enter the cell cycle. Based on the
massive epigenetic remodeling underlying the state switch,
senescence has also been linked to enhanced plasticity and
reprogramming (47). Our data strongly suggests that EPZ-6438
treatment not only suppressed MPM cell proliferation, but also
induced pro-survival pathways, which protected cancer cells from
apoptosis. EZH2 inhibition increased the expression of TG2 coding
gene, viaHIF2a (31), which in turn increased the expression of the
IL-6 gene coding for the pro-inflammatory cytokine, IL-6. IL-6 has
emerged as a mediator of pivotal processes in MPM, such as cell
proliferation and chemoresistance (48). In MPM MCS expressing
CDKN2A, blocking TG2 activity, by the selective inhibitor 1-155,
abrogated the EPZ-6438-mediated increase in IL-6 expression and
induced apoptosis (Figure 6E). While, in CDKN2A silenced MPM
MCS, EPZ-6438 treatment induced apoptosis (Figure 6D),
probably by promoting the pro-apoptotic activity of E2F1 (49).
However, the mechanistic difference between wild-type and
CDKN2A silenced MCS response to EPZ-6438 treatment needs
further and deeper investigation.
Our data support the view that treatment approaches based on
inducing p16ink4a and related G0/G1 growth arrest, in tumor cells
that lack p16ink4a, can induce tumor stabilization, but may also
enhance pro-survival signals and thereby confer resistance to
chemotherapy treatments. Deletion of CDKN2A on chromosome
9p21 is a common molecular alteration in MPM. However,
fluorescent in situ hybridization (FISH) on MPM tumor tissues
has revealed that the CDKN2A homozygous deletion cannot be
detected in all cells. Indeed, the status of the CDKN2A gene is
highly variable, with no loss, hemizygous and homozygous losses
within the same tumor. This detection of non-homogeneous
deletions of CDKN2A suggests that besides the polyclonal origin,
several genetic subclones might also exist within one tumor (8).
In conclusion, we demonstrated that, in cells with no loss or
hemizygous deletion, such as the MSTO-211H MPM cells,
CDKN2A expression can be epigenetically modulated. Translating
our findings into the clinical context, we could suggest that patients
with homozygous deletion for CDKN2A should respond to EZH2
inhibition (apoptosis). Conversely, in MPMs with wild-type
CDKN2A, a cell growth arrested phenotype would be anticipated.
Apoptosis could be augmented in a CDKN2A wild-type setting
by TG2 inhibition. In conclusion, these findings open upJuly 2021 | Volume 11 | Article 678447
Pinton et al. CDKN2A Role in EZH2 Inhibitionpossibilities for refining patient stratification and/or potentiation of
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FIGURE 6 | EZH2 inhibition in wild-type and CDKN2A silenced MPM MCS. In our MPM model, SIRT1 inhibition/silencing induced EZH2 acetylation and stability (A).
EZH2 inhibition, by EPZ-6438 treatment (B), induced the expression CDKN2A, causing cell growth arrest. Furthermore, EPZ-6438 treatment upregulated EPAS1 and
downstream TGM2 and IL6 (C). EPZ-6438 treatment induced apoptosis in CDKN2A silenced MPM MCS (D). Combined treatment with EPZ-6438 and 1-155, a
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